Subscribe

What are you looking for?

Main Menu

明報新聞網

研發肥胖症藥物生科公司質肽生物遞表申上市

Future Wealths
Future Wealths
26 4 月, 2026
One Min Read
4 Views
0 Comments
研發肥胖症及其他代謝性疾病藥物的內地生物科技公司質肽生物，上周五（24日）遞交向港交所（0388）遞表申請上市。公司去年虧損按年擴大17%至1.91億元（人民幣，下同）。收入313萬元。研發開支按年升17%至1.76億元。聯席保薦人為Jefferies及華泰國際。

原文: https://finance.mingpao.com/fin/instantf/20260426/1777199851693/%E7%A0%94%E7%99%BC%E8%82%A5%E8%83%96%E7%97%87%E8%97%A5%E7%89%A9%E7%94%9F%E7%A7%91%E5%85%AC%E5%8F%B8%E8%B3%AA%E8%82%BD%E7%94%9F%E7%89%A9%E9%81%9E%E8%A1%A8%E7%94%B3%E4%B8%8A%E5%B8%82%22%20target=%22blank

Last Update: 26 4 月, 2026

Please share this article if you like it!

Link Copied!
Future Wealths
Written By

Future Wealths

Other Articles

Related Posts

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept